Here are the 10-K annual reports from PTNTD (PTNTD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PTNTD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTNTD filings page.
Palatin Technologies, Inc. reported a net loss of $17.3 million for the year ended June 30, 2025 and management concluded there is substantial doubt about the company’s ability to continue as a going concern. The company sold its Vyleesi product assets and recorded an upfront payment of $9.5 million plus additional consideration, recognizing a $3.13 million gain on the sale and a $2.1179 million gain on eliminated purchase commitments for the fiscal year. Cash and short-term money market deposits included $2,286,603 in money market accounts at June 30, 2025 (compared with $9,089,113 at June 30, 2024). Current liabilities totaled $8,010,030 and certain current assets or balances referenced include $2,564,265. The company continues clinical development across multiple melanocortin receptor (MCR) programs, noting positive topline results reported in 2024–2025 for several programs and projected IND filings for two obesity-focused programs in early 2026. Palatin disclosed extensive financing instruments that may dilute existing shareholders, including convertible preferred stock, options, restricted stock units, and multiple series of warrants outstanding or issuable.